title: Considerations in evaluating new antianginal drugs.
abstract: Diseases that cause symptoms incompletely relieved by available modes of treatment stimulate search for new therapies. Chronic disease processes, in which interventions are palliative rather than curative provide a particular challenge in determining the value of therapeutic intervention. Management of patients with angina pectoris is an example of this challenge.
mesh_terms: D000787:Angina Pectoris / Q000188:drug therapy*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004110:Diltiazem / Q000627:therapeutic use; D004341:Drug Evaluation; D006801:Humans; D008013:Lidoflazine / Q000627:therapeutic use; D009543:Nifedipine / Q000627:therapeutic use; D012107:Research Design; D014700:Verapamil / Q000627:therapeutic use
chemical_list: D002121:Calcium Channel Blockers; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine; D008013:Lidoflazine